CME Group price target raised to $314 from $312 at Morgan Stanley

Morgan Stanley analyst Michael Cyprys raised the firm’s price target on CME Group (CME) to $314 from $312 and keeps an Overweight rating on the shares. With 80% of revenues derived from clearing and transaction fees, and a “strong moat” around its futures and options complex, the firm views CME as “best placed” in a period of ongoing macro uncertainty and renewed credit concerns, the analyst tells investors.